July, 2024
July 2024
15 Posts From ASCO24 Day 4 You Should Not Miss!
Jun 4, 2024, 14:59

15 Posts From ASCO24 Day 4 You Should Not Miss!

The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting is being held from May 31st to June 4th 2024.

Our team at OncoDaily selected the most important posts from Day 4 of ASCO24 that you should not miss.

Glad to see Dr. Philip Kantoff receive the ASCO24 Excellence in Teaching Award this past weekend.

Dr. Kantoff has inspired countless scientists, fellows, and faculty, all in service of improving the lives of cancer patients and their families.


Zainab Shinkafi-Bagudu

A wonderful evening with my AORTIC Africa family. Many issues raised around research in Africa. Comforting that organizations like ASCO and NCI are actively funding and creating opportunities for researchers in Africa.


Toni Choueiri

Poster American Society of Clinical Oncology (ASCO24) 269 by our Dana-Farber Lank Center for Genitourinary Oncology super star Eddy Saad investigates Single nucleotide polymorphism (SNP) on Interleukin-7 (IL7) associated with Immune-related adverse events (irAEs) for Nivo (HR: 2.91, P=1.9e-03) vs Evo in CM025 trial (SNPxTRT P=0.003).

Also Merit Award recipient. Direct message if you have curated irAE data to replicate!


Andrea Necchi

Interesting data from Maluf HERCULES trial in penile cancer. 40% ORR makes a compelling comparison with established TIP regimen.

PFS/OS data still poor. HPV confirms to be the Bmk of penile cancer.


Bishal Gyawali

Hey ASCO24 crowd, if you’re around drop by poster board number 62 now where my star oncology resident Dr. Kristin Wright is presenting our super interesting and important work on how “Top 10” US cancer centers recommend re cancer screening and whether those recommendations are evidence based.


Wafik S. El-Deiry

Great to run into my colleague David De Graff as we were both at Penn State News now he’s at Johnson and Johnson News.

We discussed our interest in bladder cancer at Legorreta Cancer Center at Brown University and The Warren Alpert Medical School of Brown University.

We have very high rates of bladder cancer in Rhode Island, some years we’re at 1 in the United States, or top 2-3. We don’t know why although we have good ideas.

It is a New England problem but Rhode Island is greatly affected across age groups, men and women. Rates are very very high among older men in Rhode Island.

Also telling him about opportunities for precision oncology trials in bladder cancer with the WIN Consortium.


Jun Gong

Dr. Fang Phase I trial hypoxia-responsive CEA CAR-T in refractory solid tumors (35/40 mCRC patients) enrolled to IV or IP administration depending on predominant peritoneal metastasis.

IP ORR 25% vs 8% IV, 100% G3-4 heme toxicity, G1-2 CRS 62.5% all patients.


Jennifer Marks

Management of pregnancy with lung cancer

  • No 1st trimester
  • Dose according to actual body weight
  • Maintain dose intensity
  • Don’t increase/decrease the dose
  • No chemotherapy at 35-37 of gestation
  • Minimum 3-week interval between the last cycle delivery
  • Avoid IO in 2/3 trimester


Yüksel Ürün

Every Patient is Unique, Every Story Matters! At ASCO24, we’re reminded of the diverse and inspiring journeys that ignite our passion for oncology.

Each patient’s story is a powerful testament to resilience and hope. Let’s continue to share, listen, and learn from each unique experience.


Sabine D. Brookman-May

Excellent coverage on lymph-node only metastatic Urothelial Cancer as a distinct entity among complete responders to Nivo/GC CheckMate901.

Med OS in LN-only mUC: 46.3 (Nivo+GC) vs 24.9 months with GC (HR 0.58).


American Cancer Society

At ASCO24, an annual meeting for oncology professionals, Dr. Karen Knudsen and Albert Bourla meet to discuss how cancer disproportionately impacts ethnic/racial groups.

To change these odds, this three-year initiative with Pfizer is addressing disparities in cancer care, to improve health outcomes in medically underrepresented.


Khalid El Bairi

Another great lecture from Common Sense Oncology at ASCO24. Great global initiative to empower cancer care centralized on patients.


Yale Cancer Center

Roy Herbst shared the updated results from the COAST clinical trial, a phase 2 study of durvalumab with/without oleclumab or monalizumab in patients with stage 3 unresectable NSCLC.


Conquer Cancer

We are excited and proud to share that Dr. Suresh Ramalingam, a 2006 Conquer Cancer grant recipient, was met with a standing ovation from the ASCO24 plenary session crowd as he presented breakthrough results from the phase 3 LAURA study.

Learn more about what this means for unresectable stage III non–small cell lung cancer.

Herbert Loong

With close of ASCO24, I want to thank friends of global oncology community for support as I assume the Chair of ASCO International Affairs Committee.

As an oncologist from Hong Kong, it’s a tremendous honour to take up this role. Lots to learn in the coming year!